Peptron Hits Upper Limit on Expectations of Monthly GLP-1 Supply Chain... Production Not Yet Confirmed

Peptron's shares surged to the daily price limit, driven by expectations that the company may participate in the domestic production supply chain for Eli Lilly's once-monthly GLP-1 therapy. However, the only matters officially confirmed at present are the technology evaluation for a long-acting injectable platform with Lilly and the construction of Peptron's second Osong plant. No contracts for the domestic production or commercial supply of any specific obesity treatment have been finalized.

According to the Korea Exchange on the 3rd, Peptron closed at 166,100 won, up 38,300 won (29.97%) from the previous trading day. Both the intraday high and the closing price reached the upper price limit.

Source of Market Expectations... Speculation Over 'Final Stage of Supply Chain'

The sharp rally stems from the possibility that Lilly may establish a domestic production network for its once-monthly GLP-1 class therapies. As peptide intermediate and active pharmaceutical ingredient (API) production facilities continue to emerge in the Chungcheong region, speculation has spread that Peptron, which possesses long-acting finished injectable technology, could participate in the final stage of the supply chain.

However, investors should note that the 'completion of the production belt' discussed in the market is not a business structure confirmed through official disclosure.

Confirmed Lilly Partnership via Disclosure: 'Technology Evaluation' Stage

The form of collaboration officially disclosed by Peptron is a platform technology evaluation for the application of its 'Smart Depot' technology. Specifically:

• Contract timing: In October 2024, a contract was signed for joint research and technology evaluation of a long-acting injectable formulation.
• Confidentiality: The target drug, joint research results, and commercialization status have not been disclosed.
• Management explanation: At an investor event in July, the company explained that the substance being researched with Lilly is a 'different peptide' from the specific obesity treatment widely discussed in the market.

Therefore, the interpretation that Peptron's technology is being used to formulate Lilly's existing obesity drug into a once-monthly injection is difficult to reconcile with the facts the company has publicly disclosed.

Osong Second Plant: Production Capacity Expansion vs. Confirmed Orders

The Osong second plant also needs to be viewed separately from any confirmed production contract. Peptron is currently building a cGMP-grade long-acting drug production facility aimed at entering overseas markets and is in the process of introducing automated filling equipment, which is interpreted as laying the groundwork to handle future commercial volumes.

The expansion of the plant's scale has also fueled expectations:

• Total floor area: Design changes are being pursued to increase from approximately 12,000 sqm to around 30,000 sqm.
• Funding: A significant portion of the capital raised through a 2024 rights offering is being invested in a dedicated long-acting drug production facility.

However, the plant expansion does not automatically translate into Lilly volume orders. The facility could also be utilized for Peptron's own pipeline candidates and the development and production of long-acting drugs for other pharmaceutical companies.

Three Key Variables to Verify Through Future Disclosures

1. Transition from Technology Evaluation to Technology Transfer or Joint Development Agreement A technology evaluation contract is a stage to verify the applicability of the platform. It differs in nature from a technology export agreement, which typically includes commercialization rights, upfront payments, and milestone royalties.

2. Osong Second Plant Construction Schedule and Investment Amount With the expanded area, construction costs, production equipment investment scale, and fund execution schedule may change. Given that the original completion timeline for the new plant has already been delayed, it is necessary to monitor whether groundbreaking and completion dates will be further adjusted.

3. Timing of Actual Product Selection After cGMP Facility Establishment Even after completing plant construction and equipment installation, process validation and quality management systems that meet overseas regulatory standards are required. Only when the production candidate, client, and expected volumes are specified can investors assess when facility investment will translate into revenue.

The Value of Smart Depot Technology

Peptron's 'Smart Depot' is a long-acting drug delivery technology that encapsulates drugs within biodegradable polymer microspheres, allowing them to be released at a controlled rate in the body. By extending dosing intervals, it is considered a promising approach for peptide therapeutics that require repeated administration. Based on this technology, Peptron has been developing long-acting formulations for obesity and diabetes treatments, as well as therapies for prostate cancer and acromegaly.

Conclusion: Need to Distinguish 'Confirmed Facts' from 'Market Expectations'

Today's upper-limit close appears to reflect both the technological value of Smart Depot and the potential expansion of the Osong second plant. However, the characterization of Peptron as the 'domestic production base for Lilly's once-monthly obesity drug' is closer to market speculation at this point. Until joint research results, technology transfer agreements, or specific production items are disclosed, it is necessary to separate confirmed facts from supply chain expectations.

---

[This article was written with the assistance of AI. It is intended as reference material for investment decisions and does not recommend the purchase or sale of any specific stock. Investors should review company disclosures and exchange filings before making investment decisions.]